Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising.

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, ...

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.

Novo Nordisk sued rival Eli Lilly in a U.S. federal court on ​Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.

Novo is seeking to force Lilly to pull the disputed ads and run corrective ones as the companies compete for dominance in the booming obesity drug market.

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the ...

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

A rival drug maker is taking aim at Eli Lilly in a major lawsuit, claiming the company purposely used old data in an ad ...

This wave of Hatch-Waxman cases comes as patent disputes involving GLP-1 receptor agonists, especially Novo Nordisk's Ozempic ...

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.